Cancer Family
Malignant Peritoneal and Retroperitoneal Neoplasm
CI-CAN-00000248Explore in graph →
163 active trials6 approved drugs2 evidence items
- NCIt
- C156711
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000248Explore in graph →
Clinical trials
631 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (92)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01592383 | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01669798 | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 32 | AA SecordOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT00030706 | Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | — | Montefiore Medical CenterOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Sep 17, 2018 | clinicaltrials |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00856180 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00768144 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT00301756 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2018 | clinicaltrials |
| NCT00230542 | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 2 | 44 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | completed | Phase 2 | 191 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00003453 | Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer | terminated | Phase 2 | 6 | Burzynski Research InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT03257891 | Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines(CabACC) | unknown | Phase 2 | 25 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00408070 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 2 | 5 | UConn HealthOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00499252 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01118052 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00331422 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00652899 | Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00354601 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | terminated | Phase 2 | 12 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT01905163 | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients(CILOVE) | completed | Phase 2 | 47 | Centre Jean PerrinOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00045682 | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 78 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00054119 | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | completed | Phase 2 | 20 | University of OklahomaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00061308 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | completed | Phase 2 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Jun 9, 2017 | clinicaltrials |
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | May 24, 2017 | clinicaltrials |
| NCT03145285 | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma(ABACUS) | unknown | Phase 2 | 10 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01514526 | Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | completed | Phase 2 | 17 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01137071 | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | terminated | Phase 2 | 29 | Recepta BiopharmaINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
| NCT01031381 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer(RADBEV) | completed | Phase 2 | 50 | University of PittsburghOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02595021 | Total/Subtotal Colectomy in Ovarian Cancer | unknown | Phase 2 | 80 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01283035 | A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01447706 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | completed | Phase 2 | 223 | Merrimack PharmaceuticalsINDUSTRY | 1 | May 12, 2016 | clinicaltrials |
| NCT00634894 | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00671788 | A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Apr 15, 2016 | clinicaltrials |
| NCT02324595 | Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study(MISSION) | completed | Phase 2 | 30 | Catholic University of the Sacred HeartOTHER | 1 | Apr 13, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT00008138 | S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer(S0009) | completed | Phase 2 | 62 | SWOG Cancer Research NetworkNETWORK | 0 | Jan 8, 2016 | clinicaltrials |
| NCT01091259 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | completed | Phase 2 | 29 | NYU Langone HealthOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00275028 | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT02587169 | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum(GEIS-27) | unknown | Phase 1 / Phase 2 | 40 | Broto, Javier Martín, M.D.INDIV | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00096993 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | completed | Phase 2 | 40 | Benaroya Research InstituteOTHER | 1 | May 15, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jan 15, 2019source: clinicaltrials